Details for Patent: 12,447,190
Which drugs does patent 12,447,190 protect, and when does it expire?
Patent 12,447,190 protects VASOPRESSIN IN SODIUM CHLORIDE 0.9% and is included in one NDA.
Summary for Patent: 12,447,190
| Title: | Vasopressin premix systems and uses thereof |
| Abstract: | Provided is a system comprising a flexible container for intravenous administration which comprises a premix vasopressin pharmaceutical formulation, and uses thereof. |
| Inventor(s): | II Robert W. Garber, Sydney Cope, Jason Mantei, Mark Doty |
| Assignee: | Baxter Healthcare SA , Baxter International Inc |
| Application Number: | US18/907,424 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Delivery; |
Drugs Protected by US Patent 12,447,190
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | vasopressin | SOLUTION;INTRAVENOUS | 217569-001 | Sep 29, 2023 | RX | Yes | Yes | 12,447,190 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Baxter Hlthcare Corp | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | vasopressin | SOLUTION;INTRAVENOUS | 217569-002 | Sep 29, 2023 | RX | Yes | Yes | 12,447,190 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
